Posted on

Counting down 21 days, top-level globalization summit to be held in Shanghai

Shanghai, China, October 18, 2022 – (SEAPRWire) – The EqualOcean Summit for Globalization 2022 (ESG2022) will be held in Shanghai on November 8 during the 5th China International Import Expo (CIIE) by the globalization think tank EqualOcean. The summit will focus on the third generation of global entrepreneurs and respond to China’s promotion of high-level opening up from the perspective of industry research. ESG2022 will be the first cross-boundary communication platform for entrepreneurs, investors, scholars, and diplomats. It is of special significance to hold high-level market-driven activities during the “CIIE”. Other highlights include: The “2022 China Brand Globalization Index Report” will be released and the list of “Global Brand 100” will be announced;The “Chinese Brand Globalization Resource Handbook 2022” will be released, and representative service providers in each field will be promoted;“50 Global Young Leaders in China’s globalization ” and “50 Global Leaders in China’s globalization ” will be released to express a new voice of the global generation;Senior diplomats and well-known scholars of international relations will attend and give macro guidance to global entrepreneurs;Representative enterprises from the industry chain will be present at the seminar, covering all ecosystems of globalization, and insightful communication and links will be made on-site. Some of the confirmed guests include: Lin Minwang, professor at the Institute of International Studies of Fudan University and expert on Indian issues; Li Wei, professor at Renmin University of China and expert of the United States issues; Xu Liping, researcher at the Chinese Academy of Social Sciences and expert of Southeast Asia issues; Sun Degang, professor from the Institute of International Studies of Fudan University, also an expert on Middle East issues; Wang Guanchun, founder of LAIYE Technology; Hao Yusheng, chief representative of NASDAQ China; Song Xiangqian, chairman of Harvest Capital; Li Feng, founding partner of FREES FUND Capital; Jiang Shun, partner of INCAPITAL; Shu Chang, vice-chairman of China Youth Entrepreneurs Association; Pei Yigen, vice-chairman of Shanghai Service Federation; Zhang Peng, executive chairman of Beijing Youth Entrepreneurs Association; and Wen Jing, assistant researcher of Strategy and Security Research Center Tsinghua University, etc. ESG2022’s strategic partner “Wu Jianmin Public Welfare Foundation” will coordinate several senior diplomats to attend the summit and hold a closed-door panel to give macro-level guidance to entrepreneurs who are going for globalization/going overseas. ESG2022 will invite representative platforms, consumer brands, and technology companies in globalization field, including Alibaba International, AliExpress, Amazon, TikTok, AliCloud, Meta, Anker Innovation, NIO, Geek+, NEIWAI, XAG Technology, Rokid, ninebot, moody, PatPat, Cyclone-robotics, dreame, Ecoflow, Westwell Technology, RENOGY, Roborock Technology, Insta360, CooHom, Jushuitan ERP, Muzen Radio, 42Verse, etc. In addition, the most representative venture capital firms and financial advisory firms in the globalization direction will be invited, including SEQUOIA Capital, Gaorong Capital, 5Y Capital, Blue Lake Capital, Yunqi Partners, Fosun RZ Capital, eWTP Arabia Capital, LightHouse Capital, Index Capital, Yiren Capital, Foresight Capital, Wavierider Capital, etc. ESG 2022 Agenda 9:15-9:30/ Government Official’s Address9:30-9:50/ Report release: The 2022 China Brand Globalization Index Report9:50-10:00/ Launch ceremony: Alliance for China’s Brands and Globalization & Brand Globalization Intellects10:00-10:45/ Roundtable: China’s Globalization Strategy Outlook10:45-11:30/ Roundtable: Crosstalk of a Global-born Generation11:30-12:15/ Roundtable: Opportunities for China’s Brands to Go Global – Observations from Diplomats12:15-12:20/ Award session 1: 50 Global Leaders in China’s globalization12:20-13:50/ Lunch Break14:30-14:20/ Keynote: Opportunities and Challenges for China in the Next 10 Years14:20-15:05/ Roundtable: How to Build a Global Brand15:05-15:25/ Keynote: Forging China’s Global Brands15:25-16:10/ Roundtable: Entrepreneurship Across Continents16:10-16:30/ Keynote: Infrastructure for Globalization16:30-17:15/ Roundtable: Service Providers on Building a Global Brand17:15-17:35/ Keynote: Investors’ View: Business and Investment Opportunities in the Tide of Globalization17:35-17:40/ Award session 2: TOP Investment Institutions/FA/Service Providers for China’s Globalization Our event will be held during the fifth China International Import Expo (CIIE), where national leaders, government officials, diplomats from various countries and management from famous enterprises from home and abroad will gather in Shanghai. ESG2022 will take advantage of the CIIE to raise the voice of the third generation of global entrepreneurs and respond to the national construction of high-level opening up from our perspectives. We cordially invite entrepreneurs, investors and representatives from all segments of the industry, who are interested in the direction of globalization/going abroad, to come to Shanghai on November 8 to participate and witness together. About ESG2022 and EqualOcean ESG2022, known as EqualOcean Summit For Globalization 2022, is positioned as the top industry conference that brings together the third generation of global entrepreneurs and global brands. ESG2022 will be held in Shanghai on November 8, 2022 during the fifth China International Import Expo (CIIE), and will include not only the most representative global entrepreneurs, brand leaders and investors, but also government representatives, academics, diplomats in China and representatives of international organizations. ESG2022 will release “2022 China Brand Globalization Index Report”, “2022 China Brand Globalization Resource Handbook 2022 Edition”, “2022 China 50 Young Leaders in Globalization”, “2022 China 50 Leaders in Globalization”, etc. Founded in November 2018, EqualOcean is a business information platform and think tank that focuses on Chinese brands going global and on helping overseas investors or organizations to grasp China’s development opportunities. For clients from China, EqualOcean provides macro political and economic analysis, overseas market and industry research, brand international makeup photos, overseas resource building, etc. EqualOcean has both Chinese and English websites, and is one of the very few organizations in China with the ability to write in-depth reports in English. EqualOcean’s global partners include Bloomberg Terminal, Refinitiv, SeekingAlpha, Nasdaq, ACN Newswire, SeaPRwire and other platforms. EqualOcean’s business analysts are frequently interviewed by Wall Street Journal, New York Times, Financial Times, SCMP and other well-known media outlets. ESG2022 is now in the process of registration. For more information please visit EqualOcean’s website. If you have any questions about ESG2022, please feel free to contact us at our Wechat official account or via LinkedIn(EqualOcean). Media contact Email address: lena@equalocean.com Official website: https://equalocean.com The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)

Read More
Posted on

CALB’s Listing on the Hong Kong Stock Exchange Injects Strong Positive Energy to China’s New Energy Industry

HONG KONG, Oct 6, 2022 - (ACN Newswire via SEAPRWire.com) - On October 6, CALB Co., Ltd. ("CALB" or the "Company"; stock code: 3931.HK) was officially listed on the Hong Kong Stock Exchange. The number of H Shares of the Company under the Global Offering is 265,845,300, with issue price HK$38/share and proceeds HK$ 9,863.9 million (prior to the exercise of the Over-allotment Option). The successful listing of CALB has also made it the first enterprise of power battery in Hong Kong, representing the strong positive energy of China's new energy industry.Well-recognised investment value with leading edge product portfolioRecently because of the impact of multiple factors, Hong Kong stocks continue to be lukewarm. But the company still received the attention and support of many investors which include upstream and downstream of the industrial chain and long-term investors, and the company successfully completed the stock pricing process. At the same time, the IPO of the company is one of the largest public offering in Hong Kong stock exchange this year. In the current difficult capital market, the successful pricing of such a large IPO is a huge success which also reflect the company's long-term investment value.Meanwhile, the Company has entered into cornerstone investment agreements with 15 cornerstone investors, including Tianqi Lithium HK Co., Limited, Wang Sing International Resources Limited, Han's Laser Technology Co., Limited, CNGR Hong Kong Material Science & Technology Co., Limited, XPeng Inc., vivo Mobile Communication Co., Ltd*, Jiangmen New Energy, etc. The cornerstone investors subscribed for 149,331,400 offer shares in total, representing a total of approximately 8.43% of the issued share capital of the Company immediately following the completion of the share offering and a total of approximately 56.17% of the total number of offer shares under the share offering. This indicates that institutional investors have fully recognised the investment value of CALB.According to public information, CALB is a leading new energy technology company, mainly engaged in the design, research and development, production and sales of power batteries and energy storage system products. In the first quarter of 2022, CALB ranked fifth among global third-party power battery companies and second in China in terms of installed capacity.Since its establishment, CALB has paid great attention to the technological innovation of products, and has been the leader of innovation and technology in the industry. It is a power battery enterprise with all-round independent research and development capabilities that can independently complete the production of power batteries. Its outstanding innovation capability enables the Company to develop a series of innovative core technologies and products, including high-voltage ternary battery, "magazine" battery, and "One-stop" product, which have leading advantages in energy density, safety and economy, and have been successfully installed on numerous new energy hot-selling vehicles and widely recognised by new energy vehicle manufacturers.Relying on its strong innovation capability and strong technical strength, CALB has carried out in-depth cooperation with Changan, GAC, Geely, Dongfeng and other enterprises, and currently supports 28 car companies with more than 70 models, including GAC Aion, Changan New Energy, XPeng, Geely, SGMW, FAW Hongqi, Dongfeng, Dongfeng Peugeot, Chery, Guangzhou Toyota, Guangzhou Honda, Leapmotor, HYCAN, Smart and other traditional car companies and new car manufacturers, further consolidating its position in the industry.The share price is expected to take off with huge development potential for industryAt present, driven by carbon peak emissions and carbon neutrality goal and green economic transformation, the development of renewable energy is of great significance, and new energy has become an important field for countries to compete and invest in, becoming the main battlefield of the new energy revolution.The implementation of the "double carbon" campaign and the coordinated promotion of green, low-carbon and high-quality development are constantly promoting the accelerated development of China's new energy vehicle industry. According to the Ministry of Public Security, the number of domestic new energy vehicles has exceeded 10 million in June this year, making China the world's largest new energy vehicle market.Under this backdrop, the power battery, as an important component of new energy vehicles, has huge development potential. According to estimates, the global installed capacity of power batteries will reach 1386.7GWH, nearly 1400WGH in 2026, and China's installed capacity of power batteries is expected to increase from 154.5GWH in 2021 to 762GWH in 2026.CALB will also continue to expand its production capacity. The overall effective production capacity is expected to expand to approximately 35GWh and 90GWh in 2022 and 2023, respectively, representing a year-on-year increase of up to 194% and 157%.CALB's production capacity is all high-quality that can be mass-produced to meet the full range of customer needs, which downstream customers unanimously recognize. The company's products are widely demanded in the market, and this can be expected that the impact of the company's economy of scale will continue to increase.As a benchmarking enterprise of China's power battery, CALB is bravely taking the lead at the critical moment of economic restructuring, which is not only the ambition of an enterprise, but also the best illustration of supporting China's carbon peak emissions and carbon neutrality goal. The listing of the Company as the first enterprise of power battery in Hong Kong marks the Company's official entry into the capital market, and also opens a new chapter of rapid and sustainable development for the Company. It is believed that with the help of the capital market, the Company will continue to improve the company's technical strength and product competency in the long run and strengthen the long-term competitiveness of the company , and its share price is expected to take off continuously. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Recbio Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange

HONG KONG, Mar 21, 2022 - (ACN Newswire via SEAPRWire.com) - The China-based novel vaccines company - Jiangsu Recbio Technology Co., Ltd. ("Recbio" or the "Company", stock code: 2179.HK, today announced the proposed listing of its H Shares on the Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange"). Recbio plans to offer 30,854,500 H Shares (subject to the Over-allotment Option), of which 27,769,000 H Shares will be International Placing Shares (subject to reallocation and the Over-allotment Option), representing approximately 90% of the initial Offer Shares; the remaining 3,085,500 H Shares will be Hong Kong Offer Shares (subject to reallocation), representing approximately 10% of the initial Offer Shares. Recbio will open for Hong Kong Public Offering in Hong Kong at 9:00 a.m., 21 March 2022 (Monday), and close at 12:00 noon, 24 March 2022 (Thursday). Dealings in H Shares of Recbio on the Main Board of the Hong Kong Stock Exchange is expected to commence on 31 March 2022 (Thursday). The H Shares will be traded in board lot of 500 H Shares each. The Company's stock code is 2179.HK.-- Morgan Stanley Asia Limited, CMB International Capital Limited and CLSA Capital Markets Limited are the Joint Sponsors; and Morgan Stanley Asia Limited, CMB International Capital Limited and CLSA Limited are the Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers.-- China Industrial Securities International Capital Limited, Haitong International Securities Company Limited, GF Securities (Hong Kong) Brokerage Limited, Essence International Securities (Hong Kong) Limited and Valuable Capital Limited (in relation to the Hong Kong Public Offering only) are the Joint Bookrunners and Joint Lead Managers.-- Livermore Holdings Limited is the Joint Lead Manager.A Vaccine Pipeline Driven by Novel Adjuvant TechnologyRecbio is the vaccine company with a high-value vaccine portfolio driven by in-house developed technologies. The Company is primarily focus on the R&D of HPV vaccine candidates. Its vaccine portfolio consists of 12 vaccines, including the Core Product, REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial, and the Company is one of the few domestic vaccine companies to have phase III stage HPV 9-valent vaccine candidate.In recent years, vaccinology field has entered into a new era. Advanced technologies and breakthroughs in immunology have largely reshaped the vaccinology by creating opportunities for safer and more effective vaccine solutions. According to Frost & Sullivan, subunit vaccines accounted for approximately 55.4% of China's vaccine market in 2020, which is expected to further grow to 86.6% in 2030. Driven by the growing number of subunit vaccines and technology breakthroughs, China's vaccine market is expected to grow from RMB75.3 billion in terms of production value in 2020 to RMB333.3 billion in 2030 at a CAGR of 16.0%. With its strong R&D capabilities in developing subunit vaccines, the Company believe it is well-positioned to further benefit from the overall growth of China's vaccine market.With years of dedication in developing vaccines and leveraging its in-house developed technology platforms, the Company has been built a comprehensive vaccine portfolio consisting of 12 candidates, covering a broad disease spectrum including cervical cancer, COVID-19, adult tuberculosis, shingles, HFMD and influenza. Its vaccine portfolio extends to five of the ten diseases with the greatest burden under the 2019 Global Burden of Diseases assessed by DALYs issued by the WHO and covers disease areas of the three of the top five globally bestselling vaccine products in 2020. The Core Product, REC603, is a recombinant HPV 9-valent vaccine candidate, which is currently under phase III clinical trial in China. The Company plan to submit the BLA application in 2025 for REC603 and commence commercialization once the BLA application is approved. In addition, its COVID-19 vaccine, ReCOV, has commenced a phase I clinical trial in New Zealand in June 2021 and obtained the initial partially unblinded data in October 2021. Based on the major safety and immunogenicity data and the partially unblinded efficacy data from the phase I trial, the Company subsequently obtained the clinical trial approval from the Philippines FDA to conduct the global phase II/III trial for ReCOV in January 2022. To date, the Company has initiated subject enrollment for the global phase II/III trial for ReCOV in the Philippines. In January 2022, the Company also obtained the unblinded clinical data for the remaining three cohorts and has been finalizing data analysis and clinical trial report. It plans to file the EUA/BLA application in 2022.A Pipeline of Vaccine Candidates Covering Diseases With Significant Unmet NeedsThe Company has adopted a vaccine development strategy aimed to firmly position itself at the vanguard of the vaccine industry. In light of overarching vaccine industry trends, it has strategically developed a pipeline that extends from preventative to post-exposure prophylaxis. In addition to HPV and COVID-19, its comprehensive pipeline also includes a recombinant shingles vaccine, two TB vaccines for adults, an influenza quadrivalent vaccine, and an HFMD quadrivalent vaccine.HPV vaccines are one of the most commercially valuable vaccines in the world, with a global market size of US$4.2 billion in 2020, accounting for approximately 11.5% of the global vaccine market in terms of production volume. Therefore, the Company has strategically developed a comprehensive HPV pipeline to address the unmet urgent need for HPV vaccines. To date, the Company is advancing clinical trials of three key vaccine candidates namely a recombinant HPV 9-valent vaccine, REC603, and two recombinant bivalent vaccines, REC601 and REC602, targeting different countries and populations. At present, the Company is also developing REC604a and REC604b with a potentially fewer dose regimen, employing a self-developed novel adjuvant benchmarking AS04, and plans to submit INDs filing in 2022 and 2023, respectively.What is noteworthy is that, its recombinant HPV 9-valent vaccine, REC603, is expected to be the one of the first of domestic vaccines of its kind to be approved and commercialized in China. The Company is currently conducting a phase III clinical trial and has completed 12,500 subjects enrollment for the potency tests in October 2021. The first subject was enrolled on June 26, 2021 and the Company is actively working with industry leading PIs and highly-qualified CROs to accelerate its trial progress. The Company expects to complete three-shot dosing by the first half of 2022 and plans to reach primary endpoints for its phase III clinical trial and submit BLA to the NMPA in 2025.Self-Developed Advanced Technology Platforms that Support and Drive the Development of Next Generation Vaccine CandidatesThrough years of dedication and focus on vaccinology field, the Company has developed a comprehensive vaccine innovation engine consisting of a novel adjuvant platform, protein engineering platform and immunological evaluation platform. The Company is the one of the few companies that are capable of developing novel adjuvants, benchmarking all of the FDA-approved novel adjuvants to date. The technology platforms form a solid trifecta, creating synergies among the design and optimization of antigens, the development and production of adjuvants and the identification of the optimal combinations of antigens and adjuvants. Supported by these platforms, the Company is constantly upgrading its technology to further enrich its R&D toolbox so that to drive its vaccine development going forward.In addition to the technology platforms, its IPD System lays a solid foundation for the R&D activities. The IPD system governs the entire life cycle of vaccine candidates. Empowered by the IPD System, the Company is able to advance multiple vaccine development projects simultaneously.Continuously Expand Production Capacity, Strengthen Competitive AdvantageThe company has started to build up its manufacturing capabilities at an early stage to ensure the vaccine candidates can be smoothly transferred into successful commercial vaccine products. The manufacturing and quality control system is built in compliance with the industry leading GMP standard. It also has recruited many talents in charge of production and quality, who has gained abundant industry insights and profound understanding from their commercialization experience in vaccine companies.Currently, the Company is constructing its HPV vaccine manufacturing facility in Taizhou, Jiangsu province, the first phase of which has a designed capacity of five million doses of HPV 9-valent vaccines or 30 million doses of HPV bivalent vaccines per year. The construction of the first phase of its HPV manufacturing facility is expected to be completed by the end of 2022. In addition, the Company has obtained a drug production license from ReCOV and completed the construction of the GMP-standard manufacturing facility for ReCOV in November 2021. The manufacturing facility, which can also be used for the manufacturing of recombinant shingles vaccines, has a total GFA of approximately 17,000 sq.m. and has the potential to support an annual manufacturing capacity of 300 million doses of ReCOV.High Performance Management and Scientific R&D Team, Supported by Leading Investors in the Healthcare IndustryR&D is crucial to the continuous success. The vaccine industry has been rapidly evolving with various scientific advancement and innovative technologies to constantly reshape the vaccinology field. The Company is led by an experienced management and elite scientific team consisting of industry-leading scientists with extensive experiences in academic studies of immunology and development of vaccine products and industry-leading experts who are familiar with bringing vaccine candidates from concept to market.The Company has also received strong support from its shareholders, including leading investors in healthcare industry as well as major institutional investor such as Lake Bleu Capital, Temasek, Legend Capital and Sequoia Capital, representing recognition from its shareholders on the market position and growth potential. The Company believe its diversified shareholder base will fuel the future growth with financial support and industry insights.The Chairman of the Board, Executive Director and General Manager of Jiangsu Recbio Technology Co., Ltd., Dr. LIU Yong said, "As the vaccinology field enters a new era driven by novel vaccine technologies and significant expansion in disease and population coverage, we expect that China's vaccine market will grow significantly. With our strong R&D capabilities, we expect to further benefit from the overall growth in China's vaccine market. Looking ahead, we plan to continuously accelerate R&D, clinical trial and commercialization of our vaccine candidates, including rapidly advancing the development of our HPV vaccines, COVID-19 vaccines as well as the development and commercialization of our other vaccine candidates. We also intend to boost our market penetration and profitability by encouraging continuous innovation, streamlining our organization structure, company culture, and talent recruiting system, commercializing our technologies and products in the global market, and expanding vaccine candidates and technologies internationally through collaboration. At the same time, we will continue to explore opportunities to acquire advanced technologies and recruit international talent to supplement our in-house R&D capabilities. We are also evaluating establishing an overseas R&D center to closely collaborate with academic institutes and scientists abroad and to advance our R&D activities. Finally, driven by our strong R&D capabilities, we are focusing on complete value chain innovation from R&D to commercialization in the vaccine industry, to maximize value for our shareholders and investors."Use of Proceeds:The Company estimates that it will receive net proceeds of approximately HK$672.4 million from the Global Offering, after deducting the underwriting commissions and other estimated offering expenses payable by the Company, assuming the Over-allotment Option is not exercised and assuming the Offer Price is fixed at HK$24.80 per H Share. The Company intends to use the net proceeds for the following purposes:-- Approximately 47.3%, or HK$317.9 million, will be allocated to continue to optimize, develop and commercialize HPV vaccine pipeline, including the Core Product, the recombinant HPV 9-valent vaccine REC603-- Approximately 17.7%, or HK$119.3 million, will be used for the preclinical and clinical studies, registration of the COVID-19 vaccine, namely ReCOV-- Approximately 21.1%, or HK$142.0 million, will be used for the preclinical and clinical studies, registration of other vaccine candidates, including recombinant shingles vaccine, REC610; TB vaccines, REC606; and REC607, recombinant quadrivalent influenza vaccine, REC617; and recombinant HFMD quadrivalent vaccine, REC605-- Approximately 6.7%, or HK$44.7 million, will be used to further enhance the R&D capabilities and enhance its operating efficiencies-- Approximately 7.2%, or HK$48.5 million, will be used for working capital and general corporate purposes Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Academics detail take-off of China’s ice and snow economy

HONG KONG, Mar 8, 2022 - (ACN Newswire via SEAPRWire.com) - China has seen the fastest growth of its ice and snow economy in recent years and has become the world's largest market in the sector, according to a report released by Jilin University on Thursday.Jilin University Key Laboratory of Ice and Snow Tourism Resorts Equipment and Intelligent Service Technology releases the 2022 China Ice and Snow Economic Development Index Report on Thursday. (Photo by Xu Lihua/For chinadaily.com.cn)Xin Benlu, vice-dean of the School of Business and Management at Jilin University, oversees the release of the ice and snow report at a news conference on Thursday. (Photo by Xu Lihua/For chinadaily.com.cn)Jilin University's Key Laboratory of Ice and Snow Tourism Resorts Equipment and Intelligent Service Technology, took a year to complete its 2022 China Ice and Snow Economic Development Index Report, which aims to measure and forecast China's ice and snow economic development using several ice and snow indicators.The report proposed the "airplane theory" as a way to look at the ice and snow economy.The concept uses the growing and escalating ice and snow demand, and ice and snow technology as the "airplane engine" of economic development.The specific weights of the current stage of China's ice and snow economic development is set out in the report.The "airplane's head" represents ice and snow sports, which account for 25 percent of that weight. The "airplane's fuselage" represents ice and snow tourism, which accounts for 40 percent of the weight. And the "two wings" that balance the development of the economy represent ice and snow equipment, and ice and snow culture, which account for 25 percent and 10 percent, respectively.Data shows that China's ice and snow economic development has shown a linear upward trend since the beginning of the 13th Five-Year Plan (2016-2020).Other than in 2020, with the novel coronavirus pandemic impacting the sector, each year has succeeded the previous one, ever since 2016.Driven by the Beijing 2022 Winter Olympics, the chain growth rate exceeded 34 percent in 2021, and the development of China's ice and snow economy is expected to maintain a chain growth rate of nearly 30 percent in 2022, the report said.Along with the Beijing 2022 Winter Olympics, China's ice and snow tourism will show a new face in the international arena, and attract more foreign tourists in the post-pandemic era, the report said.At the same time, with the release of Chinese people's enthusiasm for participating in and experiencing ice and snow tourism, ice and snow tourism consumption will play a massive role in boosting China's domestic demand and realizing the central domestic circulation, provincial medium circulation, and municipal microcirculation of China's ice and snow economy, the document said.Xin Benlu, vice-dean of the School of Business and Management at Jilin University, said: "The report is one of the preliminary and basic works for the construction of the big data platform of the ice and snow economy. It is expected to be released annually to measure and forecast the development of China's ice and snow economic development."Source: https://www.chinadaily.com.cn/a/202202/20/WS62113909a310cdd39bc87b2e.html Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Li Jiaqi – China’s “King of Livestreaming E-commerce” – Goes Global

HONG KONG, Aug 21, 2021 - (ACN Newswire via SEAPRWire.com) - Li Jiaqi, dubbed China's "King of Livestreaming E-commerce," is set to host a pioneering fashion show format at the iconic Shanghai K11 Art Mall on August 19-22. Li is taking Li Jiaqi WoW, his shopping information and recommendation program, offline for the first time, and will feature the involvement of five prominent Chinese designers, each based around the world. Through livestreaming, the audience will be able to communicate with the different designers as they open virtual "doors." The Shanghai show represents the beginnings of Li's grand vision as he looks to extend his influence on a global scale.Li is China's most popular key opinion leader (KOL) in the livestreaming e-commerce industry - with nearly 170 million fans - and has driven sales of more than$430 million (RMB2.8 billion) in a single live broadcast. Since 2016, livestreaming e-commerce has grown in popularity in China. Outperforming all other shopping channels, its user scale reached 388 million till December 2020, 66.2% of whom bought products via this channel, China Internet Network Information Center (CNNIC) says.Compared to traditional online shopping, livestreaming e-commerce provokes a greater consumer response through lively visual demonstrations, greater convenience, and more affordable price during the nationwide lockdown caused by the COVID-19 pandemic. Livestreaming e-commerce is especially popular during China's e-commerce festivals, such as the 618 Festival - a June festival run by many of China's e-commerce companies -with 14.2 billion views and over 100,000 brands involved in livestreaming influencer marketing in 2021.At the heart of China's livestreaming e-commerce world as well as a contributor of such accomplishment, Li Jiaqi is a force of nature. Ever since entering the industry, Li has been a trendsetter, his opinions delivered with iconic style. A "Recommended by Li Jiaqi" endorsement can truly change a company's fortunes. Florasis, a Chinese makeup brand, was one such company, quadrupling its sales year-on-year to RMB 2.75 billion after partnering with Li, rocketing them the top of Chinese makeup brands for 2020. Leveraging his powerful influence, Li has led dozens of Chinese brands to nationwide popularity, leading to him being dubbed China's "top domestic product promoter."Behind Li's to rise to fame are tags such as "Made in China," "makeup," and "lipstick," but deep down, Li has always had a greater ambition. In August last year, Li Jiaqi's team launched China's first livestreaming shopping information and recommendation program, Li Jiaqi WoW, a confluence of information on new products, available globally, across a number of categories. This shift to a more global focus is all part of Li's efforts to import designer brands around the world into China's market. Since then, Li Jiaqi WoW has aired nearly 50 episodes, eliciting a strong response across China's social platforms, such as Weibo, TikTok (Douyin), and Xiaohongshu (RED). The program is expected to further integrate offline channels as it looks to provide designers and brands with better opportunities for promotion.Li's move of promoting international brands nationwide via his livestreaming channel has worked out favorably for most featured brands. In a Salvatore Ferragamo live broadcast, for example, two hundred Salvatore Ferragamo Creation handbags, priced at RMB 17,000 each, quickly sold out.Li Jiaqi's story is not simply one of commerce and consumption, but also one that reveals the ongoing change in brand marketing and promotion in China followed by technological development and changes in Chinese people's consumption behavior.As the "door" metaphorically implies in Li Jiaqi's new product launch, live streaming e-commerce breaks borders and boundaries of space via online and offline channels, and presents brands to the market at a minimum cost, maximizing benefits for both brands and consumers. The CNNIC stated in its report that livestreaming e-commerce users made up a mere 39% of China's netizen population as of December 2020. Given the country's total internet user population of 989 million, as well as its internet penetration rate of 70%, livestreaming e-commerce is certain to grow its market share in the coming years, with data analytics company iiMedia Research predicting that by 2025, China's livestreaming influencer-led e-commerce transaction volume will reach$1 trillion (RMB 6.4 trillion). Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Livestreaming Mogul Li Jiaqi, International Brands Partner to Showcase New Products in Chinese Market

HONG KONG, Aug 21, 2021 - (ACN Newswire via SEAPRWire.com) - The arrival and subsequent evolution of livestreaming technology, and its integration with e-commerce, has radically changed China's consumer market. Different from traditional online shopping, livestreaming e-commerce features better experience and more interaction that increasingly more consumers are gravitating toward. Amid this fast-growing medium, one man stands king: Li Jiaqi.Li, China's leading influencer in the livestreaming e-commerce space, has signaled his intentions for the future - the integration of online and offline elements. From August 19-22, Li will host a pioneering fashion show at the city's iconic Shanghai K11 Art Mall. The show, where Li Jiaqi WoW will be taken offline for the first time, will see Li invite five up-and-coming Chinese designers to interact with viewers. Aside from watching all the latest deals and products, viewers can also communicate with the participating designers via livestreaming screens, set behind interactive "doors." Li is China's most popular key opinion leader (KOL) in the livestreaming e-commerce industry - with nearly 170 million fans - and has driven sales of more than$430 million (RMB2.8 billion) in a single live broadcast. Since 2016, livestreaming e-commerce has grown in popularity in China. Outperforming all other shopping channels, its user scale reached 388 million till December 2020, 66.2% of whom bought products via this channel, China Internet Network Information Center (CNNIC) says.Compared to traditional online shopping, livestreaming e-commerce provokes a greater consumer response through lively visual demonstrations, greater convenience, and more affordable price during the nationwide lockdown caused by the COVID-19 pandemic. Livestreaming e-commerce is especially popular during China's e-commerce festivals, such as the 618 Festival - a June festival run by many of China's e-commerce companies -with 14.2 billion views and over 100,000 brands involved in livestreaming influencer marketing in 2021.At the heart of China's livestreaming e-commerce world as well as a contributor of such accomplishment, Li Jiaqi is a force of nature. Ever since entering the industry, Li has been a trendsetter, his opinions delivered with iconic style. A "Recommended by Li Jiaqi" endorsement can truly change a company's fortunes. Florasis, a Chinese makeup brand, was one such company, quadrupling its sales year-on-year to RMB 2.75 billion after partnering with Li, rocketing them the top of Chinese makeup brands for 2020. Leveraging his powerful influence, Li has led dozens of Chinese brands to nationwide popularity, leading to him being dubbed China's "top domestic product promoter."Behind Li's to rise to fame are tags such as "Made in China," "makeup," and "lipstick," but deep down, Li has always had a greater ambition. In August last year, Li Jiaqi's team launched China's first livestreaming shopping information and recommendation program, Li Jiaqi WoW, a confluence of information on new products, available globally, across a number of categories. This shift to a more global focus is all part of Li's efforts to import designer brands around the world into China's market. Since then, Li Jiaqi WoW has aired nearly 50 episodes, eliciting a strong response across China's social platforms, such as Weibo, TikTok (Douyin), and Xiaohongshu (RED). The program is expected to further integrate offline channels as it looks to provide designers and brands with better opportunities for promotion.Li's move of promoting international brands nationwide via his livestreaming channel has worked out favorably for most featured brands. In a Salvatore Ferragamo live broadcast, for example, two hundred Salvatore Ferragamo Creation handbags, priced at RMB 17,000 each, quickly sold out.Li Jiaqi's story is not simply one of commerce and consumption, but also one that reveals the ongoing change in brand marketing and promotion in China followed by technological development and changes in Chinese people's consumption behavior.As the "door" metaphorically implies in Li Jiaqi's new product launch, live streaming e-commerce breaks borders and boundaries of space via online and offline channels, and presents brands to the market at a minimum cost, maximizing benefits for both brands and consumers. The CNNIC stated in its report that livestreaming e-commerce users made up a mere 39% of China's netizen population as of December 2020. Given the country's total internet user population of 989 million, as well as its internet penetration rate of 70%, livestreaming e-commerce is certain to grow its market share in the coming years, with data analytics company iiMedia Research predicting that by 2025, China's livestreaming influencer-led e-commerce transaction volume will reach$1 trillion (RMB 6.4 trillion). Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Li Jiaqi and Livestreaming, Unbound by Time or Space

HONG KONG, Aug 20, 2021 - (ACN Newswire via SEAPRWire.com) - Li Jiaqi, the most influential figure in China's livestreaming e-commerce space, recently announced his latest move - his hosting of a new fashion show at the iconic Shanghai K11 Art Mall, to be held between August 19-22. The show will feature five up-and-coming Chinese designers, based throughout the world, who will interact with visitors on the scene. It may sound like fantasy, but such reality is made possible through the implementation of livestreaming technology.At the show, visitors can check out the 2021 autumn and winter collections, while at the same time interacting with the participating designers through opening relevant "doors." As an extension of Li Jiaqi WoW, Li Jiaqi's online live shopping information & recommendation program, the show promises an immersive experience unbound by time or space and different from the conventional live streaming studio partitioned by screens. Li is China's most popular key opinion leader (KOL) in the livestreaming e-commerce industry - with nearly 170 million fans - and has driven sales of more than$430 million (RMB2.8 billion) in a single live broadcast. Since 2016, livestreaming e-commerce has grown in popularity in China. Outperforming all other shopping channels, its user scale reached 388 million till December 2020, 66.2% of whom bought products via this channel, China Internet Network Information Center (CNNIC) says.Compared to traditional online shopping, livestreaming e-commerce provokes a greater consumer response through lively visual demonstrations, greater convenience, and more affordable price during the nationwide lockdown caused by the COVID-19 pandemic. Livestreaming e-commerce is especially popular during China's e-commerce festivals, such as the 618 Festival - a June festival run by many of China's e-commerce companies -with 14.2 billion views and over 100,000 brands involved in livestreaming influencer marketing in 2021.At the heart of China's livestreaming e-commerce world as well as a contributor of such accomplishment, Li Jiaqi is a force of nature. Ever since entering the industry, Li has been a trendsetter, his opinions delivered with iconic style. A "Recommended by Li Jiaqi" endorsement can truly change a company's fortunes. Florasis, a Chinese makeup brand, was one such company, quadrupling its sales year-on-year to RMB 2.75 billion after partnering with Li, rocketing them the top of Chinese makeup brands for 2020. Leveraging his powerful influence, Li has led dozens of Chinese brands to nationwide popularity, leading to him being dubbed China's "top domestic product promoter."Behind Li's to rise to fame are tags such as "Made in China," "makeup," and "lipstick," but deep down, Li has always had a greater ambition. In August last year, Li Jiaqi's team launched China's first livestreaming shopping information and recommendation program, Li Jiaqi WoW, a confluence of information on new products, available globally, across a number of categories. This shift to a more global focus is all part of Li's efforts to import designer brands around the world into China's market. Since then, Li Jiaqi WoW has aired nearly 50 episodes, eliciting a strong response across China's social platforms, such as Weibo, TikTok (Douyin), and Xiaohongshu (RED). The program is expected to further integrate offline channels as it looks to provide designers and brands with better opportunities for promotion.Li's move of promoting international brands nationwide via his livestreaming channel has worked out favorably for most featured brands. In a Salvatore Ferragamo live broadcast, for example, two hundred Salvatore Ferragamo Creation handbags, priced at RMB 17,000 each, quickly sold out.Li Jiaqi's story is not simply one of commerce and consumption, but also one that reveals the ongoing change in brand marketing and promotion in China followed by technological development and changes in Chinese people's consumption behavior.As the "door" metaphorically implies in Li Jiaqi's new product launch, live streaming e-commerce breaks borders and boundaries of space via online and offline channels, and presents brands to the market at a minimum cost, maximizing benefits for both brands and consumers. The CNNIC stated in its report that livestreaming e-commerce users made up a mere 39% of China's netizen population as of December 2020. Given the country's total internet user population of 989 million, as well as its internet penetration rate of 70%, livestreaming e-commerce is certain to grow its market share in the coming years, with data analytics company iiMedia Research predicting that by 2025, China's livestreaming influencer-led e-commerce transaction volume will reach$1 trillion (RMB 6.4 trillion). Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Li Jiaqi, China’s “King of E-commerce Livestreaming,” to Host Interactive Fashion Show

HONG KONG, Aug 20, 2021 - (ACN Newswire via SEAPRWire.com) - Li Jiaqi, known for his successes as a livestreaming e-commerce influencer, is set to host a fashion show at the iconic Shanghai K11 Art Mallon August 19-22. The show will feature both online and offline elements, in line with recent shopping trends in China. By taking Li Jiaqi WoW, his personal shopping information and recommendation channel, offline for the first time ever, Li will encourage viewers to interact with the five participating up-and-coming Chinese designers, based around the world, via livestreaming behind the "door" (in Li Jiaqi's new product launch, the word "door" metaphorically implies the bridge between online and offline channels). Different from conventional livestreaming shows, Li Jiaqi's team has created an immersive showcase of interconnected livestreaming and e-commerce elements.Li is China's most popular key opinion leader (KOL) in the livestreaming e-commerce industry - with nearly 170 million fans - and has driven sales of more than$430 million (RMB2.8 billion) in a single live broadcast. Since 2016, livestreaming e-commerce has grown in popularity in China. Outperforming all other shopping channels, its user scale reached 388 million till December 2020, 66.2% of whom bought products via this channel, China Internet Network Information Center (CNNIC) says.Compared to traditional online shopping, livestreaming e-commerce provokes a greater consumer response through lively visual demonstrations, greater convenience, and more affordable price during the nationwide lockdown caused by the COVID-19 pandemic. Livestreaming e-commerce is especially popular during China's e-commerce festivals, such as the 618 Festival - a June festival run by many of China's e-commerce companies -with 14.2 billion views and over 100,000 brands involved in livestreaming influencer marketing in 2021.At the heart of China's livestreaming e-commerce world as well as a contributor of such accomplishment, Li Jiaqi is a force of nature. Ever since entering the industry, Li has been a trendsetter, his opinions delivered with iconic style. A "Recommended by Li Jiaqi" endorsement can truly change a company's fortunes. Florasis, a Chinese makeup brand, was one such company, quadrupling its sales year-on-year to RMB 2.75 billion after partnering with Li, rocketing them the top of Chinese makeup brands for 2020. Leveraging his powerful influence, Li has led dozens of Chinese brands to nationwide popularity, leading to him being dubbed China's "top domestic product promoter."Behind Li's to rise to fame are tags such as "Made in China," "makeup," and "lipstick," but deep down, Li has always had a greater ambition. In August last year, Li Jiaqi's team launched China's first livestreaming shopping information and recommendation program, Li Jiaqi WoW, a confluence of information on new products, available globally, across a number of categories. This shift to a more global focus is all part of Li's efforts to import designer brands around the world into China's market. Since then, Li Jiaqi WoW has aired nearly 50 episodes, eliciting a strong response across China's social platforms, such as Weibo, TikTok (Douyin), and Xiaohongshu (RED). The program is expected to further integrate offline channels as it looks to provide designers and brands with better opportunities for promotion.Li's move of promoting international brands nationwide via his livestreaming channel has worked out favorably for most featured brands. In a Salvatore Ferragamo live broadcast, for example, two hundred Salvatore Ferragamo Creation handbags, priced at RMB 17,000 each, quickly sold out.Li Jiaqi's story is not simply one of commerce and consumption, but also one that reveals the ongoing change in brand marketing and promotion in China followed by technological development and changes in Chinese people's consumption behavior.As the "door" metaphorically implies in Li Jiaqi's new product launch, live streaming e-commerce breaks borders and boundaries of space via online and offline channels, and presents brands to the market at a minimum cost, maximizing benefits for both brands and consumers. The CNNIC stated in its report that livestreaming e-commerce users made up a mere 39% of China's netizen population as of December 2020. Given the country's total internet user population of 989 million, as well as its internet penetration rate of 70%, livestreaming e-commerce is certain to grow its market share in the coming years, with data analytics company iiMedia Research predicting that by 2025, China's livestreaming influencer-led e-commerce transaction volume will reach$1 trillion (RMB 6.4 trillion). Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Sihuan Pharmaceutical(0460.HK): Respond to the special directives to combat illegal medical aesthetics services, Advocate ‘Positive Energy’ of China’s Medical Aesthetics Industry

HONG KONG, Aug 11, 2021 - (ACN Newswire via SEAPRWire.com) - On June 10, 2021, the National Health Commission, leading eight ministries and commissions, issued the "Notice on Distributing the Special Rectification Work Plan for Combating Illegal Medical Aesthetic Services." On August 9, 2021, 'The People's Daily' published an article entitled - 'Medical aesthetic sector needs to achieve best effects and prevent adverse consequences.' The article highlighted the current rectification plan in the medical aesthetic sector is to establish high industry standards, strengthen supervision, and crack down on illegal medical aesthetic services in order to create a clean and reliable medical aesthetic environment. This plan will foster new advances in medical aesthetic industry and encourage the sector's healthy development.The imported product - Letybo (botulinum toxin type A for Injection) is a medical aesthetic product produced by South Korea's Hugel Inc. Bain Capital, a well-known international private equity fund, is the controlling shareholder of Hugel Inc in South Korea. Beijing Meiyan Space Biomedicine Co., Ltd., a subsidiary of Sihuan Pharmaceutical, serves as the product's exclusive distributor across China, has long been committed to becoming a leading medical aesthetic player in China and obtained official product approval for Letybo from the China National Medical Products Administration in October 2020, becoming the first pharmaceutical company to obtain approval for this type of products from South Korea. As a 'positive energy' contributor for China's medical aesthetic industry, Sihuan Pharmaceutical has actively and dutifully responded to the special directives of the eight ministries and commissions to "combat illegal medical aesthetic services."Sihuan Pharmaceutical, like many medical aesthetic product manufacturers, actively promotes 'positive energy' associated with China's medical aesthetic industry. However, the firm has been a victim of products imported through illegal channels, which not only cause physical and mental injuries to those who seek medical aesthetic services, but also seriously hinder the sustainable development of China's medical aesthetic industry. It also runs counter to the Communist Party's philosophy of - "People's aspiration for a better life is what we strive for."Sihuan Pharmaceutical will actively cooperate with all relevant government departments to trace the root causes and provide strong evidence to aid in the firm crackdown of illegal product smuggling, illegal product manufacturing and sales, as well as illegal product transportation, while also work hard to urge all relevant Korean companies to respect and cooperate with the Chinese government's policies. This can be achieved by strictly monitoring export channels, jointly preventing and combating smuggling while ensuring the legitimacy of Korean medical aesthetic products, and protecting the interests of consumers in both countries. Sihuan Pharmaceutical will also closely cooperate with the Industry Development and Self-discipline Committee of China Plastic Surgery Association, and actively participate in the 'China Medical Aesthetic' mini programme. We will also publish a list of compliant medical aesthetic institutions that purchase products, and update it regularly to jointly promote products while also applying code scanning to verify legal product status.Sihuan Pharmaceutical, together with colleagues from all walks of life who are concerned about China's medical aesthetic sector will make untiring efforts to create a "true" and "positive" environment for China's medical aesthetic industry.Sihuan Pharmaceutical Holdings Group Ltd.Founded in 2001 and listed on the Main Board of the Hong Kong Stock Exchange Limited in 2010, Sihuan Pharmaceutical Holdings Group Ltd. ("Sihuan Pharmaceutical" or the "Company", together with its subsidiaries the "Group") (HKSE: 00460.HK) is an international pharmaceutical company led and driven by both innovation and generic, with an independent and leading independent research and development ("R&D") technology platform, a rich global product pipeline and a mature and excellent sales system. Focusing on high-growth therapeutic areas such as oncology, metabolic diseases, medical aesthetics, anti-infectives, digestive system, cardiovascular and cerebrovascular, Sihuan Pharmaceutical is building a leading medical aesthetic and biopharmaceutical leader in China with a two-wheel drive strategy of independent innovation and research and incubation to cultivate high growth new businesses. For more information on Sihuan Pharmaceutical, please visit the company website https://www.sihuanpharm.com/ Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Motor racing: China’s Zhou impresses Alonso on F1 practice debut

SPIELBERG, AUSTRIA (AFP) - China's Zhou Guanyu had his first taste of life in the Formula One fast lane on Friday (July 2) when he took the wheel of Fernando Alonso's Alpine in first practice at the Austrian Grand Prix. The 22-year-old from Shanghai who tops the F2 standings is hoping to become China's first F1 driver. And after finishing 14th in the timesheets the Alpine test driver described his morning stint at the Spielberg circuit as "amazing". "I'm happy with how I went and I definitely proved myself here, but there's still a lot of work to be done in the background and to keep improving more in the future," he added. "I'm really thankful for this opportunity - the team believing in me stepping into Fernando's car. I had to take care of it, but I was also pushing as much as I could to show my full potential." One of those impressed at his performance was his childhood hero, Alonso. "He executed FP1 perfectly in my opinion, slowly building the pace, and no stress with many things," said the two-time world champion. "So let's see if later in the year there are more opportunities for Zhou," he added. Zhou follows compatriot Ma Qinghua, who drove in several practice sessions in 2012-2013 with the HRT and Caterham teams, and Adderly Fong, who appeared in 2014 for Sauber. More on this topic   Related Story Formula One: Chinese driver Zhou to make F1 practice debut in Alonso's Alpine   Related Story Formula One: Hamilton outpaces Verstappen in practice for Austrian GP

Read More
Posted on

Cofttek, China’s Largest Manufacturer of PEA, Draws Attention of Investors

LUOHE CITY, China, Feb 14, 2021 - (ACN Newswire) - Cofttek Holding Limited, a Chinese pharmaceutical manufacturer, has recently drawn the attention of investors, following the U.S. introduction of the FDA drug ultramicronized Palmitoylethanolamide (PEA) for COVID-19 patients. Cofttek is China's largest manufacturer of ultramicronized Palmitoylethanolamide (PEA) raw materials. Following the U.S. news, orders at Cofttek have surged, and production capacity has been saturated. Cofttek founder Dr. Zeng explained, "Following this FDA news, the share price of FSD Pharma (NASDAQ: HUGE), our main competitor in the USA, roared from $3 to $14 in a few days. As the largest PEA manufacturer in China, Cofttek has attracted similar attention from many investors in the industry."About Palmitoylethanolamide (PEA): https://www.cofttek.com/product/544-31-0/Palmitoylethanolamide (PEA), an endogenous (manufactured by the body) fatty acid amide, is emerging as a new agent in the treatment of pain and inflammation. As an endogenous agent, one that is also found in foods such as eggs and milk, no serious side effects or drug-drug interactions have been identified. PEA is a naturally occurring fatty acid. It is similar to an endocannabinoid, which is one of a suite of molecules found in cannabis targeting CB2 receptors. CB2 receptors can modulate both inflammation and pain throughout the human body. COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm, which is not a virus killer. But Cofttek believes it can mitigate that immune response, which can be fatal.About CofttekCofttek Holding Limited, founded in 2008, is a high-tech pharmaceutical biochemical enterprise, integrating production, R&D and sales. It is located in Luohe Chemical Industry Park, in Luohe City, Henan Province, and is committed to the research and development of advanced pharmaceuticals, providing innovative products and high-quality services for the pharmaceutical industry.Media Contact:Dr. Zeng, Cofttek Holding LimitedE: info@cofttek.com,T: 86 1390 2465871Website: https://www.cofttek.comSource: Cofttek Holding Limited Copyright 2021 ACN Newswire. All rights reserved. www.acnnewswire.com

Read More